Scarica l'app Stockscreener
1.74
1.69%
-0.03
Pre-mercato:
1.71
-0.03
-1.72%
Precedente Chiudi:
$1.77
Aprire:
$1.76
Volume 24 ore:
341.45K
Relative Volume:
0.23
Capitalizzazione di mercato:
$16.42M
Reddito:
$356.60K
Utile/perdita netta:
$-24.32M
Rapporto P/E:
-0.1883
EPS:
-9.24
Flusso di cassa netto:
$-27.24M
1 W Prestazione:
-10.31%
1M Prestazione:
-34.09%
6M Prestazione:
-9.37%
1 anno Prestazione:
-41.39%
Intervallo 1D:
$1.71
$1.7701
Intervallo di 1 settimana:
$1.70
$2.07
Portata 52W:
$1.0901
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Nome
Geovax Labs Inc
Settore
Industria
Telefono
678-384-7220
Indirizzo
1900 LAKE PARK DRIVE, SMYRNA
Confronta GOVX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.74 | 16.42M | 356.60K | -24.32M | -27.24M | -9.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-11 | Iniziato | Alliance Global Partners | Buy |
| 2024-07-16 | Iniziato | ROTH MKM | Buy |
| 2020-11-19 | Iniziato | Maxim Group | Buy |
Geovax Labs Inc Borsa (GOVX) Ultime notizie
Stock Surge: Geovax Labs Inc (GOVX) Closes at 1.77, Marking a -7.33 Increase/Decrease - The Dwinnex
Analysts review Geovax Labs Inc’s rating - Knox Daily
GeoVax to Present Strategic Vision for Cancer and Infectious Disease Treatments at Major Biotech Conference - Citybuzz
GeoVax to Showcase Advancements in Vaccines & Immunotherapies at the 2025 BIO CEO & Investor Conference - Yahoo Finance
Trump's Stargate Initiative: A New Era For Healthcare Innovation - Evrim Ağacı
GeoVax Announces Strategic Integration of AI in Support of President Trump's Stargate Initiative - Yahoo Finance
GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital - Defense World
GeoVax Labs (NASDAQ:GOVXW) Shares Down 11.3% – Here’s Why - Defense World
GeoVax shareholders approve warrant exercises - MSN
Strengthening America's Biosecurity: GeoVax Advances Domestic Vaccine Capability - Yahoo Finance
GeoVax Advanced MVA Manufacturing Process: Aimed to Enhance Vaccine Supply Worldwide - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Labs Stockholders Approve Warrant Exercise Proposals - Defense World
GeoVax shareholders approve warrant exercises By Investing.com - Investing.com Australia
D. Boral Capital Reaffirms “Buy” Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial - Yahoo Finance
Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now - GlobeNewswire Inc.
GeoVax Achieves Significant Progress in Next-Generation COVID-19 Vaccine Development Throughout 2024 - Yahoo Finance
GeoVax to Review 2024 Progress at the Emerging Growth Conference on January 16, 2025 - Yahoo Finance
Contrasting GeoVax Labs (NASDAQ:GOVX) & Silverback Therapeutics (NASDAQ:SBTX) - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
GeoVax adjourns Special Meeting due to low quorum - Investing.com
GeoVax adjourns Special Meeting due to low quorum By Investing.com - Investing.com Australia
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent - The Manila Times
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
GeoVax Labs (GOVX) Price Target Increased by 1170.83% to 77.78 - MSN
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Geovax Labs (FRA:E8LA) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
Geovax Labs (STU:E8LA) Forward Dividend Yield % : 0.00% (As of Nov. 30, 2024) - GuruFocus.com
Alliance Global Partners Initiates Coverage of GeoVax Labs (GOVX) with Buy Recommendation - MSN
3 Penny Stocks Ready to Break Out in 2025 - sharewise
Geovax Labs (STU:E8LA) Momentum Rank : 5 (As of Nov. 27, 2024) - GuruFocus.com
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference - GlobeNewswire
GeoVax CEO to Present COVID-19 Vaccine & Cancer Therapy Updates at NobleCon20 | GOVX Stock News - StockTitan
GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks - MSN
Q4 EPS Estimates for GeoVax Labs Lifted by Noble Financial - Defense World
GeoVax Announces Positive Interim Data Review for Phase 2 - GlobeNewswire
GeoVax regains compliance with Nasdaq listing standards By Investing.com - Investing.com Australia
GeoVax regains compliance with Nasdaq listing standards - Investing.com India
GeoVax reports progress in CLL vaccine booster trial - Investing.com India
GeoVax reports progress in CLL vaccine booster trial By Investing.com - Investing.com Canada
GeoVax Labs announces interim data from Phase 2 trial of Vaccine technology - TipRanks
GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine | GOVX Stock News - StockTitan
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - The Manila Times
Analysts Set Expectations for GeoVax Labs FY2024 Earnings - Defense World
Earnings call: GeoVax reports progress in vaccine trials, financial updates By Investing.com - Investing.com Australia
ARMISTICE CAPITAL, LLC Expands Stake in Geovax Labs Inc - GuruFocus.com
Geovax Labs Inc Azioni (GOVX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.02%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):